Neurodegenerative diseases (NDDs) are a major health challenge for society; over 9.9 million new cases of dementia are identified worldwide each year, while annual care costs in Europe currently run to €130 billion. More accurate and earlier diagnosis would enable more effective treatment and improve forecasting of disease progression. Improved evaluation of NDD therapies is also needed before clinical uptake can occur.
This project aims to develop the most promising, minimally invasive, measurement methods for early NDD diagnosis and will support development of targeted (patient-specific) therapies. The project will lead to improvements in the resolution of magnetic resonance imaging (MRI) and other scanning technologies, validate biomarker measurements and develop a smartphone based cognitive test app – all designed for eventual clinical use. Measurement protocols will support standardisation for early NDD diagnosis and new therapies, enabling development of screening programmes for improved quality of life.